RU2010122934A - Фармацевтическая композиция для лечения злокачественных опухолей - Google Patents

Фармацевтическая композиция для лечения злокачественных опухолей Download PDF

Info

Publication number
RU2010122934A
RU2010122934A RU2010122934/15A RU2010122934A RU2010122934A RU 2010122934 A RU2010122934 A RU 2010122934A RU 2010122934/15 A RU2010122934/15 A RU 2010122934/15A RU 2010122934 A RU2010122934 A RU 2010122934A RU 2010122934 A RU2010122934 A RU 2010122934A
Authority
RU
Russia
Prior art keywords
interferon
receptor
ifn
type
ligand
Prior art date
Application number
RU2010122934/15A
Other languages
English (en)
Russian (ru)
Inventor
БЕРМЕХО Игнасио Хавьер МЕЛЕРО (ES)
БЕРМЕХО Игнасио Хавьер МЕЛЕРО
АРМЕНДАРИС Хуан ДУБРОТ (ES)
АРМЕНДАРИС Хуан ДУБРОТ
СТУББС Сандра ЭРВАС (ES)
СТУББС Сандра ЭРВАС
БОН Агнесса Лоранс ЛЕ (FR)
БОН Агнесса Лоранс ЛЕ
Original Assignee
Проекто Де Биомедисина Сима, С.Л. (Es)
Проекто Де Биомедисина Сима, С.Л.
Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль (Fr)
Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проекто Де Биомедисина Сима, С.Л. (Es), Проекто Де Биомедисина Сима, С.Л., Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль (Fr), Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль filed Critical Проекто Де Биомедисина Сима, С.Л. (Es)
Publication of RU2010122934A publication Critical patent/RU2010122934A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2010122934/15A 2007-11-07 2008-11-07 Фармацевтическая композиция для лечения злокачественных опухолей RU2010122934A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702961A ES2336873B1 (es) 2007-11-07 2007-11-07 Composicion farmaceutica para el tratamiento de cancer.
ES200702961.P 2007-11-07

Publications (1)

Publication Number Publication Date
RU2010122934A true RU2010122934A (ru) 2011-12-20

Family

ID=40351964

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010122934/15A RU2010122934A (ru) 2007-11-07 2008-11-07 Фармацевтическая композиция для лечения злокачественных опухолей

Country Status (11)

Country Link
US (1) US20110059045A1 (https=)
EP (1) EP2223701A1 (https=)
JP (1) JP2011503039A (https=)
CN (1) CN101951955A (https=)
AU (1) AU2008324056A1 (https=)
BR (1) BRPI0820351A2 (https=)
CA (1) CA2705105A1 (https=)
ES (1) ES2336873B1 (https=)
MX (1) MX2010005086A (https=)
RU (1) RU2010122934A (https=)
WO (1) WO2009060112A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111053918A (zh) * 2011-09-05 2020-04-24 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
TW201427681A (zh) * 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
SG11201604965RA (en) * 2013-12-20 2016-07-28 Univ Singapore Differentiation therapy with cd137 ligand agonists
EP3973980A1 (en) * 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP2399935A3 (en) * 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법

Also Published As

Publication number Publication date
MX2010005086A (es) 2010-08-10
BRPI0820351A2 (pt) 2015-10-27
ES2336873A1 (es) 2010-04-16
WO2009060112A1 (es) 2009-05-14
EP2223701A1 (en) 2010-09-01
AU2008324056A1 (en) 2009-05-14
ES2336873B1 (es) 2011-01-24
CN101951955A (zh) 2011-01-19
US20110059045A1 (en) 2011-03-10
JP2011503039A (ja) 2011-01-27
CA2705105A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
RU2010122934A (ru) Фармацевтическая композиция для лечения злокачественных опухолей
Ciardiello et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
Bocci Interleukins: clinical pharmacokinetics and practical implications
Ciardiello et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
JP2011503039A5 (https=)
JP2008507536A5 (https=)
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
Ouladan et al. Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy
Kim et al. Tumor endothelial cells as a potential target of metronomic chemotherapy.
RU2007136026A (ru) Варианты ил-21
ATE445701T1 (de) Zytokine rezeptor zcytor19
Wang et al. Trabectedin in cancers: mechanisms and clinical applications
CA2389979A1 (en) Methods of inhibiting metastasis
RU2007104053A (ru) Лечение рака
JP2009545609A5 (https=)
RU2009107085A (ru) Способы, композиции и изделия, способствующие лечению рака
JP2008523067A5 (https=)
JP2005225888A5 (https=)
Normanno et al. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
MX9805299A (es) Novedosos polinucleotidos panc1a y panc1b asociados con cancer pancreatico.
EP3315510A1 (en) Modified chemokine peptide
JP2021534750A5 (https=)
Ho et al. A novel t (2; 20)(q35; p12) in embryonal rhabdomyosarcoma
Montuori et al. 67 kDa laminin receptor (67LR) in normal and neoplastic hematopoietic cells: is its targeting a feasible approach?
Abdelhady et al. A marvelous hope in the treatment of breast cancer: Moorena producens as an incredible source of bioactive metabolites with a variety of unique selective molecular mechanisms

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130129